John Schmid
Independent, Non-executive Board Member
John Schmid has over 30 years of experience in financial and executive management in the biotechnology industry and has raised over $900 million in private and public equity and debt financings. Mr. Schmid is currently an independent board member and audit chair for Neos Therapeutics (Nasdaq: NEOS) and AnaptysBio (Nasdaq: ANAB).
He also serves as a member of the board of directors of Neos Therapeutics, Inc., AnaptysBio Inc., Forge Therapeutics, Inc., Patara Pharma, Inc., Speak, Inc. and Poseida Therapeutics Inc. Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals, which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex Pharmaceuticals, Mr. Schmid cofounded Trius Therapeutics in 2004; there, he served as CFO through its initial public offering until its sale to Cubist Pharmaceuticals in 2013 for over $700 million.
Mr. Schmid received an MBA from the University of San Diego and a BA in Economics from Wesleyan University.
Committee Roles:
Chair of the Audit Committee
Member of the Compensation Committee
He also serves as a member of the board of directors of Neos Therapeutics, Inc., AnaptysBio Inc., Forge Therapeutics, Inc., Patara Pharma, Inc., Speak, Inc. and Poseida Therapeutics Inc. Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals, which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex Pharmaceuticals, Mr. Schmid cofounded Trius Therapeutics in 2004; there, he served as CFO through its initial public offering until its sale to Cubist Pharmaceuticals in 2013 for over $700 million.
Mr. Schmid received an MBA from the University of San Diego and a BA in Economics from Wesleyan University.
Committee Roles:
Chair of the Audit Committee
Member of the Compensation Committee